Mont-Saint-Guibert, Belgique, le 13 décembre 2024, 17h30 – BIOSENIC (Euronext Bruxelles et Paris : BIOS) annonce la signature d'une lettre d’intention conditionnelle entre Medsenic SAS et la sociét
An innovative drug to treat autoimmune diseases at the source of the immune cascade.
BioSenic offers a unique treatment value by developing two innovative product lines: an arsenic trioxide-based treatment for autoimmune diseases and cell therapy products.